Literature DB >> 22783032

Tigecycline treatment of urinary tract infection and prostatitis: case report and literature review.

Duane Bates1, Mike Parkins, Robin Hellweg, Kimberly Gibson, Jennifer M Bugar.   

Abstract

Entities:  

Year:  2012        PMID： 22783032      PMCID： PMC3379828          DOI： 10.4212/cjhp.v65i3.1144

Source DB:  PubMed          Journal:  Can J Hosp Pharm        ISSN： 0008-4123


× No keyword cloud information.
  27 in total

Review 1.  Penetration of antimicrobial agents into the prostate.

Authors:  Konstantin Charalabopoulos; George Karachalios; Dimitrios Baltogiannis; Alexander Charalabopoulos; Xenofon Giannakopoulos; Nikolaos Sofikitis
Journal:  Chemotherapy       Date:  2003-12       Impact factor: 2.544

2.  Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.

Authors:  David E Nix; Kathryn R Matthias
Journal:  J Antimicrob Chemother       Date:  2010-04-08       Impact factor: 5.790

Review 3.  Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease.

Authors:  Yun Cai; Rui Wang; Beibei Liang; Nan Bai; Youning Liu
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

Review 4.  Current concepts in antimicrobial therapy against resistant gram-negative organisms: extended-spectrum beta-lactamase-producing Enterobacteriaceae, carbapenem-resistant Enterobacteriaceae, and multidrug-resistant Pseudomonas aeruginosa.

Authors:  Souha S Kanj; Zeina A Kanafani
Journal:  Mayo Clin Proc       Date:  2011-03       Impact factor: 7.616

5.  Carbapenem versus fosfomycin tromethanol in the treatment of extended-spectrum beta-lactamase-producing Escherichia coli-related complicated lower urinary tract infection.

Authors:  S Senol; M Tasbakan; H Pullukcu; O R Sipahi; H Sipahi; T Yamazhan; B Arda; S Ulusoy
Journal:  J Chemother       Date:  2010-10       Impact factor: 1.714

Review 6.  Infections with extended-spectrum beta-lactamase-producing enterobacteriaceae: changing epidemiology and drug treatment choices.

Authors:  Johann D D Pitout
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

7.  Trimethoprim-sulfamethoxazole induces reversible hyperkalemia.

Authors:  S Greenberg; I W Reiser; S Y Chou; J G Porush
Journal:  Ann Intern Med       Date:  1993-08-15       Impact factor: 25.391

8.  Rapid development of Acinetobacter baumannii resistance to tigecycline.

Authors:  Gail E Reid; Shellee A Grim; Christine A Aldeza; William M Janda; Nina M Clark
Journal:  Pharmacotherapy       Date:  2007-08       Impact factor: 4.705

9.  Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline.

Authors:  Kara B Anthony; Neil O Fishman; Darren R Linkin; Leanne B Gasink; Paul H Edelstein; Ebbing Lautenbach
Journal:  Clin Infect Dis       Date:  2008-02-15       Impact factor: 9.079

Review 10.  Clinical pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  April Barbour; Stephan Schmidt; Benjamin Ma; Lars Schiefelbein; Kenneth H Rand; Olaf Burkhardt; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447
View more
  2 in total

1.  Efficacy and safety of tigecycline for complicated urinary tract infection: a systematic review.

Authors:  Yang-Xi Liu; Ke-Jia Le; Hong-Yao Shi; Zai-Li Zhang; Min Cui; Han Zhong; Yue-Tian Yu; Zhi-Chun Gu
Journal:  Transl Androl Urol       Date:  2021-01

2.  Isolation and Characterization of a Novel Autographiviridae Phage and Its Combined Effect with Tigecycline in Controlling Multidrug-Resistant Acinetobacter baumannii-Associated Skin and Soft Tissue Infections.

Authors:  Phitchayapak Wintachai; Komwit Surachat; Kamonnut Singkhamanan
Journal:  Viruses       Date:  2022-01-20       Impact factor: 5.048
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.